Alembic Pharmaceuticals Ltd vs Lasa Supergenerics Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 754.5 as of 30 Apr 15:30 . The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 16.5 on March 2021 to 31.3 on March 2025 . This represents a CAGR of 13.66% over 5 yearsThe P/E Ratio of Lasa Supergenerics Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Alembic Pharmaceuticals Ltd changed from ₹ 18971 crore on March 2021 to ₹ 18265 crore on March 2025 . This represents a CAGR of -0.76% over 5 yearsThe Market Cap of Lasa Supergenerics Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Alembic Pharmaceuticals Ltd for the Dec '25 is ₹ 1891 crore as compare to the Sep '25 revenue of ₹ 1918 crore. This represent the decline of -1.39% The revenue of Lasa Supergenerics Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Alembic Pharmaceuticals Ltd for the Dec '25 is ₹ 264.93 crore as compare to the Sep '25 ebitda of ₹ 324.02 crore. This represent the decline of -18.24% The ebitda of Lasa Supergenerics Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Alembic Pharmaceuticals Ltd changed from ₹ 134.54 crore to ₹ 131.95 crore over 7 quarters. This represents a CAGR of -1.10% The net profit of Lasa Supergenerics Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Alembic Pharmaceuticals Ltd changed from 25.09 % on March 2021 to 42.97 % on March 2025 . This represents a CAGR of 11.36% over 5 yearsThe Dividend Payout of Lasa Supergenerics Ltd changed from 4.46 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world.
The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited.
The company is engaged in pharmaceuticals business.
As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

About Lasa Supergenerics Ltd

Lasa Supergenerics Limited was incorporated on March 11, 2016.
The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing.
The Company is a veterinary API manufacturing entity, which was acquired in April, 2012.
The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra.
It specialises in catalyst chemistry' and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India.

FAQs for the comparison of Alembic Pharmaceuticals Ltd and Lasa Supergenerics Ltd

Which company has a larger market capitalization, Alembic Pharmaceuticals Ltd or Lasa Supergenerics Ltd?

Market cap of Alembic Pharmaceuticals Ltd is 14,830 Cr while Market cap of Lasa Supergenerics Ltd is 39 Cr

What are the key factors driving the stock performance of Alembic Pharmaceuticals Ltd and Lasa Supergenerics Ltd?

The stock performance of Alembic Pharmaceuticals Ltd and Lasa Supergenerics Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alembic Pharmaceuticals Ltd and Lasa Supergenerics Ltd?

As of May 4, 2026, the Alembic Pharmaceuticals Ltd stock price is INR ₹754.5. On the other hand, Lasa Supergenerics Ltd stock price is INR ₹7.96.

How do dividend payouts of Alembic Pharmaceuticals Ltd and Lasa Supergenerics Ltd compare?

To compare the dividend payouts of Alembic Pharmaceuticals Ltd and Lasa Supergenerics Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.